Development of second-generation probiotics as radiation mitigators

NIH RePORTER · NIH · N01 · $43,965 · view on reporter.nih.gov ↗

Abstract

The University of Pittsburgh and the University of Wisconsin have developed a Lactobacillus reuteri-based cytokine delivery platform (LRC-DP) to mitigate acute gastrointestinal radiation syndrome (GI-ARS) and has licensed this technology to ChromoLogic. ChromoLogic has developed a LRC-DP construct that produces the cytokines IL-22 or IFN-β and plans to test efficacy in animal models of GI-ARS.

Key facts

NIH application ID: 11088007
Project number: 75N93021C00008-P00011-9999-1
Recipient: CHROMOLOGIC, LLC
Principal Investigator: CLAUDE ROGERS
Activity code: N01
Funding institute: NIH
Fiscal year: 2024
Award amount: $43,965
Award type: —
Project period: 2021-03-16 → 2025-03-15